Pay in 4 interest-free payments of $5.24 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
It allows individuals to eat less without persistent hunger while promoting healthier eating habits by stabilizing blood sugar and reducing cravings
Ive pointed patients to Noom for exactly that reason, and now that the GLP-1 Companion is free, its something I can offer everyone I start on these medications
Real-world safety data from the FDA Adverse Event Reporting System suggests that Mounjaro may actually have lower pancreatitis risk compared to some other GLP-1 receptor agonists: Mounjaro (tirzepatide): Adjusted ROR 2.74 (suggests the reporting rate is about 2.7 times higher than would be expected if there was no association) Liraglutide (Saxenda): ROR 4.76 (suggests the reporting rate is about 4.8 times higher than expected, making it higher risk than Mounjaro) Semaglutide (Wegovy/Ozempic): ROR 2.04 (suggests the reporting rate is about 2 times higher than expected, slightly lower than Mounjaro) Dulaglutide (Trulicity): ROR 2.01 (suggests the reporting rate is about 2 times higher than expected, slightly lower than Mounjaro) While these numbers may seem complicated, they suggest that Mounjaros pancreatitis risk is comparable to or lower than that of other medications in the same class, with liraglutide showing a notably higher risk signal
coined the term inflammaging to describe the chronic, low-grade, and systemic inflammation that occurs with age [71]
It adds that a personal or family history of medullary thyroid cancer, polycythemia vera, or sleep apnea calls for detailed risk-benefit discussion and closer monitoring if treatment proceeds
Progress check-ins help keep you motivated, supported, and on track
